8-K: Pulmonx Reshuffles Leadership, French Returns as CEO

Pulmonx Corporation announced a significant leadership transition, reappointing Glendon E. French as President and CEO and Derrick Sung as COO and CFO, alongside preliminary Q3 2025 revenue of $21.5 million.

Summary

• Pulmonx Corporation announced a leadership transition with the reappointment of Glendon E. French as President and Chief Executive Officer, effective October 27, 2025.
• Derrick Sung was appointed Chief Operating Officer and Chief Financial Officer, effective November 3, 2025.
• Steven S. Williamson resigned as President, CEO, and Board member, effective October 27, 2025.
• Mehul Joshi resigned as Chief Financial Officer, effective October 27, 2025.
• Both Mr. Williamson and Mr. Joshi will serve in advisory capacities through December 1, 2025, to ensure a smooth transition, receiving consulting fees of $50,000 and $30,000 respectively, and continued equity vesting during this period.
• Preliminary, unaudited total worldwide revenue for the third quarter of 2025 is expected to be approximately $21.5 million.
• The third quarter 2025 financial results release and earnings call have been rescheduled to November 12, 2025.

Sentiment

Score: 6

Explanation: The simultaneous departure of the CEO and CFO introduces uncertainty, but the immediate appointment of experienced replacements, including a former CEO and CFO with deep company and industry knowledge, suggests a planned and orderly transition. The preliminary revenue figure lacks context for a definitive assessment, but the continuity provided by the returning executives and the structured advisory period for the outgoing leaders offers some stability.

Positives

• Return of experienced leadership: Glendon E. French, a former Pulmonx CEO with over 25 years in interventional pulmonology, is reappointed CEO.
• Derrick Sung, a former Pulmonx CFO, returns as COO and CFO, bringing prior company and industry experience.
• Orderly leadership transition facilitated by consulting agreements for outgoing executives until December 1, 2025.
• New executives receive substantial equity awards, aligning their interests with long-term shareholder value.
• Sign-on bonuses of $50,000 for Mr. French and $200,000 for Dr. Sung.

Negatives

• Resignation of both the President/CEO and CFO simultaneously could signal instability or underlying issues, despite the company stating it's not due to disagreements.
• Preliminary Q3 2025 revenue of $21.5 million is provided without context of previous guidance or analyst expectations, making it difficult to assess if it's a positive or negative surprise.
• The performance stock unit (PSU) vesting condition for new executives requires the average closing price of common stock to be greater than $4.00 per share over 60 consecutive trading days, which might indicate current stock price is below this threshold or that significant growth is needed.
• Rescheduling of the Q3 2025 earnings call to November 12, 2025, could create uncertainty among investors.

Risks

• Forward-looking statements are subject to risks and uncertainties, some of which cannot be predicted or quantified, and actual results may differ materially from expectations.
• Factors that could cause actual results to differ materially are detailed in the Risk Factors section of Pulmonx's public filings, including the Quarterly Report on Form 10-Q filed on August 1, 2025.
• The preliminary, unaudited revenue results are estimates only and are subject to revision until full financial results are reported.
• The company's ability to successfully integrate new leadership and maintain operational continuity during the transition period.
• The performance condition for PSUs (stock price > $4.00) implies a risk if the stock does not reach or sustain this level.

Future Outlook

Pulmonx plans to provide further details on its third quarter results and full year outlook during its rescheduled third quarter 2025 earnings call on November 12, 2025. The company aims to improve the lives of patients with severe emphysema and create significant value for all stakeholders.

Management Comments

• "The Board is confident in our decision to bring Glen and Derrick back into these leadership roles. We fully expect that their deep operational experience and strategic clarity will ensure the success and stability our stakeholders expect." Dana G. Mead, Jr., Chairperson of the Board.
• "With over twenty-five years of experience in interventional pulmonology, including a decade as CEO of Pulmonx, Glen is ideal to lead the company into our next chapter, and we are pleased with his decision to return." Dana G. Mead, Jr., Chairperson of the Board.
• "On behalf of the Board, I would also like to thank Steve and Mehul for their efforts and wish them success in their future endeavors." Dana G. Mead, Jr., Chairperson of the Board.
• "I am excited to return to lead the team at Pulmonx in its efforts to improve the lives of the many patients with severe emphysema. I am confident that there is a significant value creation opportunity for all our stakeholders, and I look forward to working with Derrick and the entire Pulmonx team to ensure that we are delivering results for our customers and their patients while also taking a renewed focus on creating value for our shareholders." Glen French, President and Chief Executive Officer of Pulmonx.

Industry Context

Pulmonx operates in the medical device industry, specifically focusing on minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The re-appointment of a seasoned leader like Glendon French, with extensive experience in interventional pulmonology, suggests a strategic move to leverage deep industry knowledge and potentially re-energize growth or address specific market challenges. The company's Zephyr Valve is a key product, recognized as a standard of care, indicating its strong position within its niche. The leadership changes could be aimed at reinforcing its market position or navigating competitive pressures within the medical device sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Significant impact due to leadership changes, preliminary revenue announcement, and rescheduled earnings call. The performance-based equity awards for new executives (stock price > $4.00) directly tie their compensation to shareholder value creation.
• Employees: Changes in top leadership can affect morale and strategic direction. The consulting agreements for outgoing executives aim for a smooth transition.
• Customers/Patients: The new CEO's stated focus on improving the lives of patients with severe emphysema suggests continued commitment to the company's mission and product offerings.
• Suppliers/Creditors: No direct impact mentioned, but leadership stability can indirectly influence business relationships.

Next Steps

• Pulmonx Corporation will release its full third quarter 2025 financial results and host a conference call on November 12, 2025.
• Steven S. Williamson and Mehul Joshi will serve in advisory capacities until December 1, 2025.
• Glendon E. French's RSU will vest in equal quarterly installments over three years, and PSU vesting is subject to time-based and performance conditions (stock price > $4.00).
• Derrick Sung's RSU will vest 25% after one year, then in equal installments over twelve subsequent quarters, and PSU vesting is subject to time-based and performance conditions (stock price > $4.00).

Key Dates

Recommendation

The simultaneous departure of the CEO and CFO creates immediate uncertainty, which typically warrants caution. However, the swift appointment of highly experienced replacements, including a former CEO and CFO with deep company and industry knowledge, provides a degree of stability and suggests a well-managed transition. The preliminary Q3 revenue of $21.5 million is presented without context of prior guidance or analyst expectations, making it difficult to assess its implications. Investors should await the full Q3 results and the rescheduled earnings call on November 12, 2025, for a clearer picture of the company's financial health and strategic direction under the new leadership before making definitive buy or sell decisions. The performance-based equity for new executives (stock price > $4.00) indicates a clear target for value creation, but its achievement remains to be seen.

Keywords

Pulmonx Corporation, LUNG, CEO change, CFO appointment, management transition, Q3 2025 revenue, Glendon French, Derrick Sung, Steven Williamson, Mehul Joshi, medical device, COPD, Zephyr Valve, executive compensation, SEC filing, corporate governance